You are here

VRTX

$147.41

0.00%

Investor Relations

News & Events

Filter Releases
 
Press Releases
Date Title and Summary View
Oct 25, 2017
-Third-quarter 2017 cystic fibrosis product revenues of $550 million, up 34% versus Q3 2016; $336 million for ORKAMBI and $213 million for KALYDECO- -Company increases total 2017 CF product revenue guidance to $2.10 to $2.15 billion; increases ORKAMBI revenue guidance to $1.29 to $1.32 bi...
Apr 27, 2017
-First-quarter 2017 cystic fibrosis product revenues of $481 million; $295 million for ORKAMBI and $186 million for KALYDECO- -Company reiterates 2017 guidance for ORKAMBI product revenues of $1.1 to $1.3 billion and increases 2017 guidance for KALYDECO product revenues to $710 to $730 million- ...